At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
News|Videos|December 14, 2015
Off-Label Uses for NOACs
Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic gives examples of certain off-label uses for NOACs that seem promising.
Advertisement
Katie Greenlee, PharmD, BCPS-AQ Cardiology, of the Cleveland Clinic gives examples of certain off-label uses for NOACs that seem promising.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.
Advertisement
Related to this article
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
4
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
5